Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for High Risk Diabetic Retinopathy
NCT03452657Phase 3Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2018
- Primary completion
- Jun 2019
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in diabetic retinopathy (DR) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Proportion of eyes with a ≥ 2-step improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) score at 1 year. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03452657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452657.